GSK (LON:GSK) Shares Cross Above 200 Day Moving Average – Should You Sell?

GSK plc (LON:GSK) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,961.64 and traded as high as GBX 1,989.50. GSK shares last traded at GBX 1,958, with a volume of 6,270,777 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on GSK shares. Shore Capital Group reiterated a “buy” rating on shares of GSK in a report on Wednesday, March 25th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 price objective on shares of GSK in a report on Thursday, May 28th. Berenberg Bank reiterated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a report on Thursday, March 26th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,900 price objective on shares of GSK in a report on Monday, June 8th. Finally, Citigroup lowered their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of GBX 2,034.29.

GSK Stock Performance

The company has a quick ratio of 0.73, a current ratio of 0.79 and a debt-to-equity ratio of 106.74. The company’s fifty day simple moving average is GBX 1,974.91 and its 200 day simple moving average is GBX 1,961.64. The stock has a market capitalization of £78.52 billion, a price-to-earnings ratio of 13.78, a P/E/G ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last released its quarterly earnings results on Wednesday, April 29th. The company reported GBX 46.50 EPS for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. The business had revenue of GBX 762.90 billion for the quarter. On average, equities research analysts expect that GSK plc will post 175.980975 earnings per share for the current year.

Insider Transactions at GSK

In other news, insider Anne Beal acquired 196 shares of GSK stock in a transaction on Friday, March 20th. The shares were purchased at an average cost of GBX 5,179 per share, for a total transaction of £10,150.84. Also, insider Jonathan Symonds acquired 5,000 shares of GSK stock in a transaction on Friday, March 20th. The shares were purchased at an average price of GBX 1,951 per share, for a total transaction of £97,550. Over the last ninety days, insiders have acquired 9,619 shares of company stock valued at $19,452,794. 0.31% of the stock is currently owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.